SafeSEQ Panel

NSCLC

The SafeSEQ NSCLC panel is a clinical grade, ultra-sensitive liquid biopsy solution for the identification of gene mutations, shown in the table below, associated with Non-Small Cell Lung Cancer (NSCLC).

The SafeSEQ NSCLC panel is a clinical grade, ultra-sensitive liquid biopsy solution for the identification of gene mutations associated with Non-Small Cell Lung Cancer (NSCLC). The table shows genes, gene regions covered (amino acids), and clinical relevance.

The SafeSEQ NSCLC panel delivers equivalent performance with broader genomic coverage than testing with OncoBEAM™ digital PCR (dPCR).  Further, the assay demonstrates ultra-sensitive detection of low-frequency mutations, with a calling threshold of 5 MM (0.025% MAF for 20,000 GE DNA input), while specificity remains very high.

SafeSEQ and OncoBEAM testing demonstrates 99.6% overall agreement for the detection of mutations in EGFR, KRAS, and BRAF, with a strong positive correlation between MAF values across a broad dynamic range, as seen in the figure above.

  1. Sloane, H; Sathyanarayan, P.; Edelstein, D., Jones, F.; Preston, J; Wu, S; Los, J.; Duchstein, L.; Fredebohm, J.; Wichner, K.; Heim, D.; et al. Clinical evaluation of NGS-based liquid biopsy genotyping in non-small cell lung cancer (NSCLC) patients. Cancer Res July 1 2021 (81) (13 Supplement) LB053; DOI: 10.1158/1538-7445.AM2021-LB053

More Ultra-sensitive SafeSEQ Panels

Interested in learning more about our ultra-sensitive SafeSeq Panels?